SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 84 filers reported holding SEELOS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $57,360 | +43.1% | 48,000 | -17.2% | 0.00% | 0.0% |
| Q1 2023 | $40,090 | +7.4% | 58,000 | +5.5% | 0.00% | 0.0% |
| Q4 2022 | $37,345 | -34.5% | 55,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $57,000 | -29.6% | 55,000 | -53.5% | 0.00% | 0.0% |
| Q2 2022 | $81,000 | -18.2% | 118,400 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $99,000 | -48.7% | 118,400 | 0.0% | 0.00% | -66.7% |
| Q4 2021 | $193,000 | -35.5% | 118,400 | -4.4% | 0.00% | -25.0% |
| Q3 2021 | $299,000 | -28.6% | 123,900 | -22.0% | 0.00% | -33.3% |
| Q2 2021 | $419,000 | -57.8% | 158,900 | -20.1% | 0.01% | -60.0% |
| Q1 2021 | $992,000 | +497.6% | 198,800 | +89.3% | 0.02% | +400.0% |
| Q4 2020 | $166,000 | +348.6% | 105,000 | +162.5% | 0.00% | +200.0% |
| Q3 2020 | $37,000 | -79.8% | 40,000 | -78.0% | 0.00% | -75.0% |
| Q2 2020 | $183,000 | +94.7% | 181,500 | -5.0% | 0.00% | +100.0% |
| Q1 2020 | $94,000 | – | 191,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 508,000 | $249,000 | 0.10% |
| 1492 Capital Management LLC | 150,000 | $74,000 | 0.09% |
| Uniplan Investment Counsel, Inc. | 2,069,121 | $1,014,000 | 0.08% |
| ARDSLEY ADVISORY PARTNERS LP | 70,000 | $34,000 | 0.01% |
| Spark Investment Management LLC | 35,210 | $17,000 | 0.01% |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 191,000 | $94,000 | 0.00% |
| WealthPLAN Partners, LLC | 20,000 | $15,000 | 0.00% |
| Procyon Advisors, LLC | 2,500 | $1,000 | 0.00% |
| Renaissance Technologies | 1,078,379 | $529,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |